Human Clinical Evidence To date, only three small human pilot studies of BPC-157 have been published in peer-reviewed medical literature: Knee Pain Study (2021): A pilot study examined 16 patients with chronic knee pain who received BPC-157 injections
reported greater weight loss in obese mice with the GLP-1/GIP/glucagon receptor triagonist compared to GLP-1 receptor agonists, GIP/GLP-1 receptor co-agonists and GLP-1/glucagon receptor agonists including semaglutide and tirzepatide [60]
AOD 9604, HGH Fragment 176-191, and 5-Amino-1MQ operate through entirely different pathways and lack the large-scale RCT data supporting the GLP-1 class
Metabolic Support : It plays a role in fat and protein metabolism, which may aid weight management
Angiognesis : induce expresin de VEGF-R2 (KDR) y activa la va VEGF-R2/Akt/eNOS, promoviendo formacin de neo-vasos en sitios de lesin
Tirzepatide Once Weekly for the Treatment of Obesity